Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist

Autor: H. Kakizawa, Y. Itoh, S. Imamura, T. Matsumoto, Y. Ishiwata, Y. Ono, K. Yamamoto, T. Kato, N. Hayakawa, N. Oda, Y. Goto, A. Nagasaka, T. Senda, M. Itoh
Rok vydání: 2004
Předmět:
Blood Glucose
Male
Vascular Endothelial Growth Factor A
medicine.medical_specialty
Endocrinology
Diabetes and Metabolism
Clinical Biochemistry
Blotting
Western
Tetrazoles
Angiotensin II receptor antagonist
Angiotensin-Converting Enzyme Inhibitors
Pharmacology
Kidney
Biochemistry
Streptozocin
Diabetes Mellitus
Experimental
Diabetic nephropathy
chemistry.chemical_compound
Angiotensin Receptor Antagonists
Endocrinology
Enalapril
Internal medicine
medicine
Albuminuria
Animals
Diabetic Nephropathies
Rats
Wistar
Antihypertensive Agents
Analysis of Variance
Endothelin-1
business.industry
Biochemistry (medical)
Biphenyl Compounds
Kidney metabolism
General Medicine
medicine.disease
Angiotensin II
Rats
Vascular endothelial growth factor
Candesartan
chemistry
Enalapril Maleate
ACE inhibitor
Disease Progression
Benzimidazoles
business
Diabetic Angiopathies
medicine.drug
Zdroj: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 36(7)
ISSN: 0018-5043
Popis: Two endothelium-derived factors, endothelin (ET), a vasoconstrictor, and vascular endothelial growth factor (VEGF), an angiogenic factor are thought to be involved in the pathogenesis of diabetic vascular complications. The aim of this study was to determine the effects of an angiotensin II type I (AT-1) receptor antagonist and an ACE inhibitor on the pathogenesis of VEGF and ET-1-mediated kidney disease in STZ-induced diabetic rats. Two days after STZ administration, diabetic rats were treated for 8 weeks with enalapril maleate, an ACE inhibitor, candesartan cilexetil, an AT-1 receptor antagonist, or saline. Urinary albumin and N-acetyl beta-D glucosaminidase (NAG) excretion as well as the VEGF protein content in the kidney were all found to be elevated in diabetic rats. Administration of enalapril maleate or candesartan cilexetil decreased the level of microalbuminuria and NAG excretion in diabetic rats. Administration of enalapril maleate also suppressed the elevated renal VEGF protein content in these animals while candesartan cilexetil treatment had no effect. Serum ET-1 and VEGF levels were unchanged by these treatments. These data support a role for AT-1 receptor antagonists and ACE inhibitors in the prevention of diabetic nephropathy, and suggest that the former may work by reducing renal VEGF levels.
Databáze: OpenAIRE
Externí odkaz: